Makarov Danil V, Holmes-Rovner Margaret, Rovner David R, Averch Timothy, Barry Michael J, Chrouser Kristin, Gee William F, Goodrich Kate, Haynes Mike, Krahn Murray, Saigal Christopher, Sox Harold C, Stacey Dawn, Tessier Christopher, Waterhouse Robert L, Fagerlin Angela
American Urological Association Education and Research Inc., Linthicum, Maryland.
Urol Pract. 2018 Nov;5(6):444-451. doi: 10.1016/j.urpr.2017.11.005. Epub 2017 Dec 4.
The American Urological Association Quality Improvement Summit occurs regularly to provide education and promote dialogue around the issues of quality improvement and patient safety. Nearly all prostate cancer screening guidelines recommend shared decision making strategies when determining whether prostate specific antigen testing is right for a specific patient. This summit, held in partnership with the Society for Medical Decision Making, focused on techniques to identify and understand patient values in relation to prostate cancer screening and treatment, and to promote incorporation of shared decision making into prostate cancer screening discussions.
Information presented at the Quality Improvement Summit was provided by physicians and leading experts in the field of shared decision making. The open forum of this summit encouraged contributions from participants about their personal experiences with shared decision making and their thoughts on the tools presented during the day.
Shared decision making supports collaboration between physician and patient in situations where there are multiple preference sensitive options.
Practitioners should include formal shared decision making procedures surrounding prostate specific antigen testing in their practices to ensure that testing is in accordance with patient values and desired outcomes. Tools and strategies like those reviewed in this Quality Improvement Summit are invaluable for alleviating potential burden on providers, ensuring communication and improving quality of care.
美国泌尿外科学会质量改进峰会定期召开,旨在围绕质量改进和患者安全问题提供教育并促进对话。几乎所有前列腺癌筛查指南都建议,在确定特定患者是否适合进行前列腺特异性抗原检测时采用共同决策策略。本次峰会与医学决策学会合作举办,重点关注识别和理解患者在前列腺癌筛查及治疗方面的价值观的技巧,并推动将共同决策纳入前列腺癌筛查讨论中。
质量改进峰会上展示的信息由共同决策领域的医生和顶尖专家提供。本次峰会的开放论坛鼓励参与者分享他们在共同决策方面的个人经历以及他们对当天展示的工具的看法。
在存在多种偏好敏感选项的情况下,共同决策支持医生与患者之间的协作。
从业者应在其医疗实践中纳入围绕前列腺特异性抗原检测的正式共同决策程序,以确保检测符合患者价值观和预期结果。像本次质量改进峰会上所回顾的那些工具和策略,对于减轻医疗服务提供者的潜在负担、确保沟通以及提高医疗质量非常宝贵。